 Merck & Co.’s drug Zetia proved effective at reducing risk of heart attacks, strokes and other heart problems in a large, long-awaited trial, marking a milestone in the 40-year-old battle to fight cardiovascular disease by lowering cholesterol.. The benefit was modest—a 6.4% reduction in all cardiovascular events— in a high-risk, aggressively treated population of patients. But it was the first time that adding a non-statin cholesterol fighter to the blockbuster statin class of cholesterol-lowering medicines was shown to...
  